PLX
Protalix BioTherapeutics, Inc.
Key Financials
Net Income
$-6604000
↓ 325.2%
Operating Income
$-5500000
↓ 240.4%
Gross Profit
$4.0M
↑ 400.7%
Revenue
$52.7M
↓ 1.2%
Total Assets
$82.3M
↑ 12.2%
EPS (Diluted)
$-0.08
↓ 300.0%
Cash & Equivalents
$14.7M
↓ 25.7%
Total Liabilities
$34.1M
↑ 12.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| S-8 | 8/12/2026 | View on SEC |
| 10-Q | 8/12/2026 | View on SEC |
| 8-K | 8/12/2026 | View on SEC |
| SCHEDULE 13G | 7/29/2026 | View on SEC |
| 8-K | 6/25/2026 | View on SEC |
| 8-K | 5/21/2026 | View on SEC |
| 10-Q | 5/13/2026 | View on SEC |
| 8-K | 5/13/2026 | View on SEC |
| ARS | 4/30/2026 | View on SEC |
| DEF 14A | 4/30/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | PLX |
| Company Name | Protalix BioTherapeutics, Inc. |
| CIK | 1006281 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | NYSE |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 201-696-9345 |